000			01357 a2200373 4500
005			20250517052553.0
264		0	_c20170919
008			201709s 0 0 eng d
022			_a1578-2190
024	7		_a10.1016/j.ad.2015.07.006 _2doi
040			_aNLM _beng _cNLM
100	1		_aPuig, L
245	0	0	_aModel for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain. _h[electronic resource]
260			_bActas dermo-sifiliograficas _c
300			_a34-43 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab _xtherapeutic use
650	0	4	_aBiological Products _xeconomics
650	0	4	_aDecision Trees
650	0	4	_aEtanercept _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aInfliximab _xtherapeutic use
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aPsoriasis _xdrug therapy
650	0	4	_aReproducibility of Results
650	0	4	_aSpain
650	0	4	_aUstekinumab _xtherapeutic use
700	1		_aLópez-Ferrer, A
700	1		_aVilarrasa, E
700	1		_aGarcía, I
700	1		_aFernández-del Olmo, R
773	0		_tActas dermo-sifiliograficas _gvol. 107 _gno. 1 _gp. 34-43
856	4	0	_uhttps://doi.org/10.1016/j.ad.2015.07.006 _zAvailable from publisher's website
999			_c25256468 _d25256468